An exon 21 L858R EGFR mutation is associated with a decreased survival... | Download Scientific Diagram
Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients? | BMC Cancer | Full Text
EGFR Exon 20 Insertions
Overall survival in patients with EGFR exon 20 insertions and major... | Download Scientific Diagram
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC | NEJM
Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study - The Lancet Regional Health –
Differences among lesions with exon 19, exon 21 EGFR mutations and wild types in surgically resected non-small cell lung cancer | Scientific Reports
Kaplan-Meier survival analysis of patients with NSCLC with or without... | Download Scientific Diagram
A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes | SpringerLink
Critical Review of *EGFR*-Mutated NSCLC What We Do and Do Not Know | Published in healthbook TIMES Oncology Hematology
The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study | Scientific Reports
THE LIVES AFFECTED BY EGFR EXON 20 INSERTION MUTATIONS
Cancers | Free Full-Text | A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses
Overall survival (OS) curves of EGFR‑mutated patients treated with... | Download Scientific Diagram
The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer | Scientific Reports
Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients? | BMC Cancer | Full Text
Structure-based classification predicts drug response in EGFR-mutant NSCLC | Nature
Association between EGFR exon 19 or exon 21 mutations and survival rates after first‑line EGFR‑TKI treatment in patients with non‑small cell lung cancer
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002) | Scientific Reports
Overall survival of EGFR-mutated lung adenocarcinoma patients with or... | Download Scientific Diagram
Frontiers | Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies
The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis | Scientific Reports
Survival‑associated factors of first‑line EGFR‑tyrosine kinase inhibitor responders and non‑responders in lung adenocarcinoma patients with common EGFR mutations
Patients with advanced non‑small cell lung cancer with EGFR mutations in addition to complex mutations treated with osimertinib have a poor clinical outcome: A real‑world data analysis
Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort - ScienceDirect
